Suki AI

Suki AI, Inc. is a healthcare AI company focused on reducing clinician administrative burden through voice-enabled, ambient technology. Founded to build an 'invisible' assistant for doctors, Suki has grown into what it positions as clinical infrastructure, partnering with over 300 health systems including a strategic relationship with MedStar Health.

The company has raised roughly $168 million in total funding across multiple rounds, most notably a $70 million Series D in October 2024 led by Hedosophia (with Venrock and existing investors March Capital, Flare Capital, Breyer Capital, and inHealth Ventures), valuing the company at about $500 million. An additional Series D extension in early 2025 was reported with Zoom Ventures involvement. Notable backers and advisors include Venrock, Flare Capital, Breyer Capital, and Salesforce CEO Marc Benioff.

Suki's core products are Suki Assistant, a full voice assistant supporting ambient scribing, dictation, and command modes with deep bi-directional EHR integration, and Suki Compose, a lighter documentation app without native EHR integration. The assistant ambiently generates structured clinical notes, pulls patient context (vitals, allergies, labs), suggests ICD-10 and E/M codes, and answers clinical questions conversationally.

Underpinning the products is the Suki Speech Platform, an SDK and API suite that lets other healthcare software vendors embed Suki's ambient and voice capabilities. Suki runs on iOS, Android, web, and Windows desktop, and supports multilingual patient input. Its differentiator is the depth of EHR write-back across Epic, Oracle Health, athenahealth, and MEDITECH combined with a broader assistant feature set than pure note-taking scribes.

Suki primarily serves hospitals, large health systems, and multi-provider group practices that use supported EHRs (Epic, Oracle Health, athenahealth, MEDITECH) and want to reduce documentation burden and clinician burnout. Its per-clinician, enterprise contract model with annual commitments and quote-based pricing makes it a fit for organizational buyers rather than individual solo practitioners on tight budgets. The Suki Speech Platform additionally targets healthcare software vendors and digital health developers.

Approximately $168 million raised in total. Key round: $70 million Series D (October 2024) led by Hedosophia with Venrock, valuing Suki at about $500 million; earlier rounds include a $55 million Series C (2021) led by March Capital and a $20 million Series B (2020) led by Flare Capital. A Series D extension in early 2025 was reported with Zoom Ventures.